Genetic Susceptibility to Kidney Cancer
Recruitment status was: Recruiting
|Renal Cell Carcinoma|
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Genetic Susceptibility to Renal Cell Carcinoma|
We will utilize the blood collected to run several laboratory analyses that will assess DNA damage/repair, telomere length, telomerase activity, and other genetic instability as predictors of RCC risk. All information linking this unique identifier to the participant will be kept in a secure location under lock-and-key password protected.
In addition, RCC tumor and adjacent normal tissue samples may be obtained from the MDACC Institutional Tissue Bank (ITB) for cases only. The samples obtained will be left over from surgical procedures, so as to prevent any additional distress to the patient.
|Study Start Date:||July 2008|
|Estimated Study Completion Date:||July 2014|
|Estimated Primary Completion Date:||July 2013 (Final data collection date for primary outcome measure)|
Healthy adults, of any ethnicity, or sex, and with no previous history of cancer, except for non-melanoma skin cancer
Adult patients with newly diagnosed (diagnosed within the year of enrollment) renal carcinoma (RCC) any ethnicity, or sex, who have not received prior chemotherapy or radiotherapy.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00854022
|Contact: Carmen Bedfordfirstname.lastname@example.org|
|United States, Texas|
|MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: XIFENG WU 713-745-2485 email@example.com|
|Sub-Investigator: Richard E. Link, MD, PhD|
|Sub-Investigator: Brian J. Miles, MD|
|Principal Investigator:||Seth P. Lerner, MD||Baylor College of Medicine|